Stoke Therapeutics, Inc. (STOK) Earnings
Stoke Therapeutics, Inc. is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.73. STOK has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise +18.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.80 | $-0.79 | +1.3% | $6M | -3.9% |
| Nov 4, 2025 | $-0.54 | $-0.65 | -20.4% | $11M | +133.4% |
| Aug 12, 2025 | $-0.57 | $-0.40 | +29.8% | $14M | +158.0% |
| Mar 18, 2025 | $-0.51 | $-0.18 | +64.7% | $23M | +485.9% |
| May 4, 2023 | $-0.70 | $-0.53 | +24.3% | $5M | +71.7% |
| Mar 6, 2023 | $-0.72 | $-0.65 | +9.7% | $3M | +14.2% |
| Nov 14, 2022 | $-0.69 | $-0.66 | +4.3% | $3M | +6.7% |
| Mar 10, 2022 | $-0.62 | $-0.66 | -6.5% | — | — |
| Aug 10, 2021 | $-0.49 | $-0.60 | -22.4% | — | — |
| Mar 9, 2021 | $-0.43 | $-0.42 | +2.3% | — | — |
| Nov 12, 2020 | $-0.42 | $-0.41 | +2.4% | — | — |
| May 15, 2020 | $-0.37 | $-0.34 | +8.1% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Thomas started by introducing the call. Ian then discussed the company's progress over the past 12 - 18 months, including increased awareness of the company due to advocacy and education related to Dravet syndrome and Zariva - Nursen. Barry reviewed four - year longitudinal data from Phase 1 - 2 Open Label Extension Studies, and updated on Phase 3 Emperor Study enrollment. Jason spoke about commercial planning for potential US launch, including patient population, genetic testing, and medical affairs efforts. Thomas provided financial results for the first quarter of 2026.
Guidance
Phase 3 EMPEROR study is on track to complete enrollment in June 2026, with data readout expected in mid - 2027 and rolling NDA submission starting in Q1 2027. The company has over $400 million on the balance sheet, funded well beyond Phase III readout and through potential US launch. They expect a lean commercial infrastructure given the concentrated Dravet syndrome market.
Risks & headwinds
Forward - looking statements are subject to risks and uncertainties, actual results may differ materially. Risks related to clinical study outcomes, regulatory approvals, and market acceptance of Zariva - Nursen.
Analyst Q&A
Q: For the four - year data, how do these outcomes for both seizure reduction and the Vinland align with expectations and how they add to what's seen for Zareva - Nursin, and about variability in subdomains?
A: Pete was answered by Ian and Barry. Ian said they were thrilled with the data showing root - cause treatment, and Barry said the results were as hoped with consistency and durability. Regarding variability, it's due to adding patients as they reach milestones in the open - label extension study.
Q: Barry, walk through key numbers again, and Ian or Jason on market appreciation of Zeromanersen's value?
A: Barry mentioned 130 patients randomized, 91 received loading doses or sham, 18 completed week 28 visit. Jason said payers look at totality of data, appropriate analogs are other genetically targeted disease - modifying medicines like Spinraza, and they are educating payers through national account directors.
Q: Confidence in hitting key secondaries in Phase 3 and US stats analysis for NDA?
A: Ian said data helps understand mechanistic pathway. Barry said Phase 3 study was powered based on prior data, has confidence in showing statistical significance in subdomains, and FDA looks at composite and individual subdomains.
Q: How OLE data gets on the label, specific examples of long - term data on label?
A: Laura was answered by Ian, Jason, and Barry. Ian said label is for safety and efficacy, industry guidance supports supplementary data in label. Jason gave examples like Spinraza, Skyclaris, Kalsodi. Barry mentioned predetermined endpoint in OLE data.
Q: Pricing discussion with payers, addressable population of 6,000?
A: Mark was answered by Ian. Payers look at totality of evidence including longitudinal data. 6,000 addressable is based on epi analysis of 25 or younger patients and claims data.
Q: Rolling submission timeline, Europe patients?
A: Garen was answered by Ian. Anticipate start rolling submission in Q1 2027, won't wait for Europe data for filing.
Q: 6K population, adult patients, penetration percentage?
A: Tom was answered by Jason and Barry. Adult patients have seizures and quality of life as objective. Enthusiasm is high due to data and medical affairs efforts.
Q: Payers requiring patients to fail anti - seizure meds before Zorevinircin?
A: Joey was answered by Ian. Don't see it as a roadblock as patients are treated with anti - seizure meds before genetic test.
Q: SG&A trajectory, Stoke 002 data, baseline demographics of Emperor trial?
A: Adam was answered by Ian and Barry. SG&A is lean. Stoke 002 may see efficacy data in late 2027 or early 2028. Baseline demographics are consistent with past screening but specifics not disclosed.
Q: Missing key secondary endpoints and use of natural history data for payer discussion?
A: Rudy was answered by Ian. Primary endpoint allows approval, secondaries and OLE data support label. Natural history data helps establish medicine's value to payers.